E M McGlashan1, L S Nandam2, P Vidafar1, D R Mansfield1,3, S M W Rajaratnam1, S W Cain4. 1. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, 3800, Australia. 2. Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. 3. Monash Lung and Sleep, Monash Health, Clayton, VIC, Australia. 4. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, 18 Innovation Walk, Clayton, VIC, 3800, Australia. sean.cain@monash.edu.
Abstract
RATIONALE: Disturbances of the circadian system are common in depression. Though they typically subside when depression is treated with antidepressants, the mechanism by which this occurs is unknown. Despite being the most commonly prescribed class of antidepressants, the effect of selective serotonin reuptake inhibitors (SSRIs) on the human circadian clock is not well understood. OBJECTIVE: To examine the effect of the SSRI citalopram (30 mg) on the sensitivity of the human circadian system to light. METHODS: This study used a double-blind, placebo-controlled, within-subjects, crossover design. Participants completed two melatonin suppression assessments in room level light (~ 100 lx), taking either a single dose of citalopram 30 mg or a placebo at the beginning of each light exposure. Melatonin suppression was calculated by comparing placebo and citalopram light exposure conditions to a dim light baseline. RESULTS: A 47% increase in melatonin suppression was observed after administration of an acute dose of citalopram, with all participants showing more suppression after citalopram administration (large effect, d = 1.54). Further, melatonin onset occurred later under normal room light with citalopram compared to placebo. CONCLUSIONS: Increased sensitivity of the circadian system to light could assist in explaining some of the inter-individual variability in antidepressant treatment responses, as it is likely to assist in recovery in some patients, while causing further disruption for others.
RCT Entities:
RATIONALE: Disturbances of the circadian system are common in depression. Though they typically subside when depression is treated with antidepressants, the mechanism by which this occurs is unknown. Despite being the most commonly prescribed class of antidepressants, the effect of selective serotonin reuptake inhibitors (SSRIs) on the human circadian clock is not well understood. OBJECTIVE: To examine the effect of the SSRI citalopram (30 mg) on the sensitivity of the human circadian system to light. METHODS: This study used a double-blind, placebo-controlled, within-subjects, crossover design. Participants completed two melatonin suppression assessments in room level light (~ 100 lx), taking either a single dose of citalopram 30 mg or a placebo at the beginning of each light exposure. Melatonin suppression was calculated by comparing placebo and citalopram light exposure conditions to a dim light baseline. RESULTS: A 47% increase in melatonin suppression was observed after administration of an acute dose of citalopram, with all participants showing more suppression after citalopram administration (large effect, d = 1.54). Further, melatonin onset occurred later under normal room light with citalopram compared to placebo. CONCLUSIONS: Increased sensitivity of the circadian system to light could assist in explaining some of the inter-individual variability in antidepressant treatment responses, as it is likely to assist in recovery in some patients, while causing further disruption for others.
Authors: Tracey L Sletten; Simon Vincenzi; Jennifer R Redman; Steven W Lockley; Shantha M W Rajaratnam Journal: Front Neurol Date: 2010-11-01 Impact factor: 4.003
Authors: Angus C Burns; Richa Saxena; Céline Vetter; Andrew J K Phillips; Jacqueline M Lane; Sean W Cain Journal: J Affect Disord Date: 2021-08-27 Impact factor: 4.839
Authors: Davide Elia Bertani; Antonella Maria Pia De Novellis; Riccardo Farina; Emanuela Latella; Matteo Meloni; Carmela Scala; Laura Valeo; Gian Maria Galeazzi; Silvia Ferrari Journal: Int J Environ Res Public Health Date: 2021-02-09 Impact factor: 3.390
Authors: Kathryn A Roecklein; Peter L Franzen; Delainey L Wescott; Brant P Hasler; Megan A Miller; Shannon D Donofry; Caitlin M DuPont; Sarah M Gratzmiller; Scott P Drexler; W Michael Wood-Vasey; Paul D Gamlin Journal: J Affect Disord Date: 2021-05-02 Impact factor: 6.533
Authors: Andrew J K Phillips; Parisa Vidafar; Angus C Burns; Elise M McGlashan; Clare Anderson; Shantha M W Rajaratnam; Steven W Lockley; Sean W Cain Journal: Proc Natl Acad Sci U S A Date: 2019-05-28 Impact factor: 11.205
Authors: Camilla M Hoyos; Christopher Gordon; Zoe Terpening; Louisa Norrie; Simon J G Lewis; Ian B Hickie; Sharon L Naismith Journal: BMC Psychiatry Date: 2020-04-29 Impact factor: 3.630
Authors: Danielle J Houwing; Jolien de Waard; Anouschka S Ramsteijn; Tom Woelders; Sietse F de Boer; Emma J Wams; Jocelien D A Olivier Journal: Psychopharmacology (Berl) Date: 2020-06-12 Impact factor: 4.530
Authors: Sean W Cain; Elise M McGlashan; Parisa Vidafar; Jona Mustafovska; Simon P N Curran; Xirun Wang; Anas Mohamed; Vineetha Kalavally; Andrew J K Phillips Journal: Sci Rep Date: 2020-11-05 Impact factor: 4.379
Authors: Mirjam Münch; Anna Wirz-Justice; Steven A Brown; Thomas Kantermann; Klaus Martiny; Oliver Stefani; Céline Vetter; Kenneth P Wright; Katharina Wulff; Debra J Skene Journal: Clocks Sleep Date: 2020-02-28